Corbus Pharmaceuticals Holdings, Inc. (CRBP) |
|
0.1289 0.006 (4.54%)
|
12-07 16:00 |
|
Open: |
0.1212 |
Pre. Close: |
0.1233 |
|
High:
|
0.1289 |
Low:
|
0.1131 |
|
Volume:
|
3,411,604 |
Market Cap:
|
16(M) |
|
|
|
Technical analysis |
as of: 2022-12-07 4:21:19 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.21 One year: 0.26 |
| Support: |
Support1: 0.1 Support2: 0.08 |
| Resistance: |
Resistance1: 0.18 Resistance2: 0.22 |
| Pivot: |
0.12  |
| Moving Average: |
MA(5): 0.13 MA(20): 0.12 
MA(100): 0.18 MA(250): 0.3 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 18.1 %D(3): 21 |
| RSI: |
RSI(14): 48.9 |
| 52-week: |
High: 0.73 Low: 0.1 |
| Average Vol(K): |
3-Month: 5,259 (K) 10-Days: 16,467 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRBP ] has closed below upper band by 48.1%. Bollinger Bands are 55.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.13 - 0.13 |
0.13 - 0.13 |
|
Low:
|
0.11 - 0.11 |
0.11 - 0.11 |
|
Close:
|
0.13 - 0.13 |
0.13 - 0.13 |
|
Company Description |
|
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. |
Headline News |
Thu, 01 Dec 2022
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session By Benzinga - Investing.com UK
Thu, 01 Dec 2022
Is Corbus Pharmaceuticals Holdings Inc (CRBP) a Winner in the Biotechnology Industry? - InvestorsObserver
Wed, 30 Nov 2022
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.18% By Investing.com - Investing.com
Wed, 30 Nov 2022
Should You Buy Corbus Pharmaceuticals Holdings Inc (CRBP) Stock After it Is Higher By 81.82% in a Week? - InvestorsObserver
Wed, 30 Nov 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
Wed, 16 Nov 2022
Children – The Next Business Agenda: evolution of CRBP from principles to practice - Global Prime News
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
125 (M) |
| Shares Float |
125 (M) |
|
% Held by Insiders
|
0.4 (%) |
|
% Held by Institutions
|
19 (%) |
|
Shares Short
|
4,760 (K) |
|
Shares Short P.Month
|
3,720 (K) |
Stock Financials |
|
EPS
|
-0.32 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.64 |
|
EPS Est Next Year
|
-0.69 |
|
Book Value (p.s.)
|
0.34 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-22 |
|
Return on Equity (ttm)
|
-69.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.29 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.27 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-40 (M) |
|
Levered Free Cash Flow
|
-21 (M) |
Stock Valuations |
|
PE Ratio
|
-0.42 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.37 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.41 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
